GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

GH Research PLC (GHRS) — Alignment with FDA on CMC and device plans for Phase 3Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estatePhase 2a results in postpartum depression published in The Journal of Clinical PsychiatryCash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026 DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming

Source: GlobeNewswire — read the full announcement there.

See our GH Research company profile for background, links, and more GH Research news.